| Biomarker ID | 1926 |
| PMID | 25786615 |
| Year | 2013 |
| Biomarker | miR-562 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa [mean PC/mean]: (14.66 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathway include: Gene expression (Transcription); DNA binding; RNA Polymerase II Transcription; nucleic acid binding; organic cyclic compound binding |
| Experiment | Prostate Cancer Vs Benign Prostatic hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | Samples from 13 BPH patients (controls), 11 patients with localized PC (LPC), 9 patients with lymph node metastases (N1) or distant metastases (M1), and 11 patients with castration resistant PC (CRPC) were selected |
| Senstivity | 45% |
| Specificity | 100% |
| AUC | 0.720 (95% CI: 0.570-0.869) |
| Accuracy | NA |
| Level Of Significance | p=0.01 |
| Method Used | miRCURY LNA microRNA PCR |
| Clinical | No |
| Remarks | Specificity fixed at 100%, sensitivity is calculated accordingly |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |